Kornimate/medical-research-clean huggingface dataset:
18f-labeled picolinamide pet imaging of melanoma diagnosis

Conditions: Melanoma

Summary: the purpose of this study is to assess the dosimetric properties of the positron emission tomography (pet) imaging probe 18f labeled picolinamide (18f-p3bza) and preliminarily evaluate its diagnosis value in melanoma patients.

50 patients with pathology diagnosed melanoma will be enrolled for the clinical study. if agree to take part in this study, the patient will be performed with 18f-p3bza pet/ct scan and 18f-fdg pet/ct scan in the other day before and after surgery. next, all of the resected tissues from the patients will be checked with pathology. 6 of 50 patients are performed for whole-body pet scans at 0, 15, 30, 45, 60, and 120 minutes and a ct scan at 60 minutes after tracer injection (mean dose, 5.0 ± 0.5 mci in 2.0 ± 0.5ml) will be performed. during the imaging period, 1 ml blood samples will be obtained for time-activity curve calculations at 1, 5, 10, 30,60, 90, 120, and 180 minutes after injection. the estimated radiation doses will be calculated by using olinda/exm software. the images produced by these scans will be compared to see the diagnosis value of 18f-p3bza. screening tests: women who decide to take part in this study will be asked if they think they might be pregnant at the start of the study. all of them must have a negative blood pregnancy test (human chorionic gonadotropin, hcg). pet-ct scan procedure: before the pet-ct scan is performed, patient will be asked to remove any metallic objects when she/he arrive at the pet-ct center. after a property rest, he/she will be injected with about 5mci 18f-p3bza. the first scan will take at 60 minutes after injection and a delay scan will take at 120 minutes after injection. each pet/ct scan will take about 20 minutes. after 18f-p3bza scan, the patient will be asked to avoid stressful exercise. starting about 12 hours before 18f-fdg scan, he/she will be asked to limit the amount of carbohydrates until the scans are done. follow-up visits: patients' primary care physician will follow-up them for next 24 hours. after then, they may order additional imaging or surgical results after this study for follow-up purposes. the study doctor will review these results to compare them with the pet-ct images. the study doctors will also review the results of any biopsies you may have had as a result of pet-ct findings. this is an investigational study. pet-ct and ct scans are fda approved and commercially available.

Eligibility criteria:
inclusion criteria: * patients with melanoma: diagnosed by pathology and ready for surgery exclusion criteria: * patients with melanoma: refuse or cannot endure surgery * pregnant women

Keywords: picolinamide pet/ct diagnosis melanoma
the chronic kidney disease adaptive platform trial investigating various agents for therapeutic effect

Conditions: Chronic Kidney Diseases

Summary: captivate is an international, multi-centre, phase iii, adaptive, platform, randomised controlled trial in people with chronic kidney disease (ckd). captivate aims to find the best treatment, or combination of treatments, that slow the progression of ckd so that fewer people develop kidney failure. captivate provides a research platform that allows many treatment-related questions to be answered within a common trial set-up.

chronic kidney disease (ckd) affects over 800 million people globally and is projected to be the 5th most common cause of death by 2040. ckd progresses to kidney failure, increases the risk of early death, heart disease, and leads to a poorer quality of life. current treatments do not entirely remove the risk of kidney failure in people with ckd. to improve the outcomes of people with ckd, it is crucial to find the best treatment or combination of treatments that can slow ckd progression. captivate aims to address this need. captivate has been designed to test multiple treatments within a common research platform. this design is more efficient and will lead to a shorter time for patients to receive effective treatments. the trial is 'eternal', which means that participants will continue to be recruited for many years until the trial is finally wound up. it is also 'adaptive', providing the flexibility to add new treatments, or remove those that are not working. participants can participate in more than one treatment at the same time or at different times. participants receive each study treatment for 2 years. for each treatment, participants are followed up at study visits that occur at approximately one month, 3 months, 6 months, 12 months, 18 months and 2 years after starting treatment. a final study visit occurs one month after the end of the 2-year treatment phase. information collected at study visits include blood and urine test results, safety assessments and treatment adherence. information about the overall health status of each participant is collected every 5 years.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. known chronic kidney disease from any cause (egfr ≥25 ml/min/1.73m2) 3. currently receiving standard of care treatment according to treating physician 4. eligible for randomisation in at least one recruiting domain-specific appendix 5. participant and treating physician are willing and able to perform trial procedures exclusion criteria: 1. planned to commence kidney replacement therapy or kidney transplant surgery in next 6 months 2. life expectancy less than 6 months

Keywords: chronic kidney disease mineralocorticoid receptor antagonist finerenone
the effect of wavelet index in monitoring the sedation depth of remimazolam besylate

Conditions: Remimazolam; Anesthesia Awareness; Sedative, Hypnotic, or Anxiolytic Withdrawal

Summary: to explore the sedative effect of remimazolam in patients undergoing spinal anesthesia without pain stimulation. both the modified observer's assessment of alertness/sedation (moaa/s) and the wavelet index (wli) were used to monitor the depth of anesthesia of remimazolam, and exploring the correlation and consistency between moaa/s score and wli value at the same time.

patients undergoing spinal anesthesia were received remimazolam besylate for sedation continuously. both the modified observer's assessment of alertness/sedation (moaa/s) and the wavelet index (wli) were used to monitor the depth of anesthesia of remimazolam, and exploring the correlation and consistency between moaa/s score and wli value at the same time.

Eligibility criteria:
inclusion criteria: * asa was classified as i-iii * the operation time was less than 120 minutes * informed consent is signed by all study participants * elective lower extremity surgery under spinal anesthesia was performed exclusion criteria: * pregnant or lactating women * patients with difficult airways * history of severe neurological and muscular diseases and mental retardation * patients with severe respiratory and circulatory diseases, including acute heart failure. unstable angina pectoris. resting ecg heart rate \<50 beats/min. qtc: ≥470ms in men and ≥480ms in women. third degree atrioventricular block. severe arrhythmia. moderate to severe heart valve disease. chronic obstructive pulmonary disease. a history of severe asthma. * abnormal liver and kidney function: alt and/or ast exceeding 2.5 times the upper limit of the medical reference range * take diazole drugs and/or opioids in one month or nearly three months * patients who were allergic to or contraindicated to benzodiazepines, opioids, propofol, flumazenil, naloxone, etc * patients who could not monitor the depth of anesthesia for various reasons

Keywords: wavelet index remimazolam depth of sedation
electromyographic´s differences between dry needling in tonic or phasic skeletal muscle fibers.

Conditions: Muscle Disorder; Trigger Point Pain, Myofascial

Summary: the aim of this study is to compare the surface electromyography (egm) changes between dry needling in the upper trapezius, is a prevalence tonic fiber or lower trapezius is a prevalence phasic fiber.

several studies already found a disturbed surface electromyography activity in myalgic muscle tissue and in the vicinity of myofascial trigger points, however studies about the effect of dry needling in this fibers type on these disturbances in emg activity are scarce. the surface electromyography of upper trapezius is related with a tonic muscle dysfunction, for example muscle contracture; and the lower fiber of trapezius is related with atrophy muscle. dry needling is an effective method for the treatment of myofascial trigger points for immediate reduction of pain. there are some studies about latent myofascial trigger point and motor activity, but we don't know any research about the effect of dry needling in the differences fibers.

Eligibility criteria:
inclusion criteria: * presence latent myofascial trigger point in the upper/lower trapezius asymptomatic subjects exclusion criteria: * neck or shoulder pain at the moment or 6 month ago. whiplash injury previous spine or shoulder surgery pregnancy diagnosis of radiculopathy or myelopathy

Keywords: surface electromyographic dry needling
vega prospective kiel

Conditions: Degenerative Osteoarthritis; Rheumatoid Arthritis

Summary: voluntary post-marketing clinical follow-up (pmcf) as part of the post marketing surveillance plan for the product under investigation. for this pmcf only ce-marked medical devices have been used and will be used within their intended purpose and no additional invasive or other stressful examinations have been or are to be carried out (acc. to mpg §23b).

this non-interventional clinical study (nis) is conducted to clinically confirm the safety and performance of the aesculap® vega system® ps components under routine conditions. the vega system® ps is an established tka design, and there is a long-lasting experience in the use of ps components in particular; thus a nis is thought to be sufficient to give the required confirmation. for this nis only ce-marked medical devices have been used and will be used within their intended purpose and no additional invasive or other stressful examinations have been and are to be carried out (acc. to mpg §23b). this voluntary nis is part of the post-marketing surveillance for the product under investigation.

Eligibility criteria:
inclusion criteria: * patient has received primary tka at the study site five to six years ago using the product under investigation because of the following severe knee joint conditions that could not be treated through other therapies: * degenerative osteoarthritis, * rheumatoid arthritis, * posttraumatic arthritis, * symptomatic knee instability, knee stiffness or deformation of the knee joint * age at the time of surgery ≥ 18 years * patient signed informed consent exclusion criteria: * age younger than 18 years at the time of surgery * any prior joint replacement at the index knee * patient did not sign informed consent * all cases not listed under indications (according to ifu) * all cases showing any contraindication (according to ifu)

Keywords: total knee arthroplasty total knee replacement tka tkr stiffness of knee deformity knee joint instability post-traumatic arthrosis
eight-weeks of treatment with talnetant in subjects with irritable bowel syndrome (ibs)

Conditions: Irritable Colon

Summary: this study will evaluate the effectiveness and safety of the investigational drug talnetant in treating subjects with irritable bowel syndrome (ibs).


Eligibility criteria:
inclusion criteria: * subjects will be required to conduct self-assessments of their ibs symptoms using a touch-tone telephone system for the duration of the study (15 weeks). * must be diagnosed with ibs consistent with the rome ii criteria. * must have normal results from a colonic procedure within 2 years of randomization. * must have conducted self-assessments on at least 12 days and have a documented average ibs pain or discomfort score of greater than or equal to 1.5 during the two-week screening phase. exclusion criteria: * self-assessment of no stool for 7 days during the two-week screening phase. * clinically significant abnormal laboratory tests. * current evidence or history of various conditions, comorbidities, or surgeries such as irritable bowel disease (ibd), gastrointestinal surgeries, and diverticulitis. * inability to use the touch-tone telephone system. * hypersensitivity to quinolone antibiotics or quinolone derivatives. * diagnosis of a psychiatric disorder within the past 2 years and not on a stable dose of medication for at least 6 months. * women who are pregnant, breast feeding, or planning to become pregnant during the study. permitted medications: the subject is allowed to take any of the following medications, provided they maintain a stable dose for at least 30 days prior to the screening visit and throughout the remainder of the study: * antidepressants, except remeron * antihypercholesterolemics * iron supplements * bulking agents * fiber supplement * thyroid replacement therapy (levothyroxine) * antipsychotics * cox-2 inhibitors (celebrex) prohibited medications: subjects must stop taking any medications they are taking to treat their ibs symptoms and must not have taken any of the prohibited medications at least 7 days prior to the screening visit and must remain off these medications for the duration of the study. * anticholinergics (dicyclomine, hyoscyamine, propantheline) * cholinomimetic (bethanechol, pyridostigmine, tacrine, physostigmine) * all narcotics (morphine, codeine, tylenol #3, propoxyphene, either alone or in combination) * tramadol hydrochloride (ultram) * colchicine * orlistat (xenical) * misoprostol, alone or in combination (arthrotec, cytotec) * 5-ht3 receptor antagonists (ondansetron, tropisetron, dolasetron, granisetron, mirtazapine, cilansetron, alosetron) * tegaserod (zelnorm) * gabapentin * lupron * antacids containing magnesium or aluminium * antidiarrheal agents * bismuth compounds * prokinetic agents (cisapride, metoclopramide) * sulfasalazine * laxatives * cholestyramine

Keywords: quality of life irritable bowel syndrome ibs sb223412 qol
prostatic resection cavity stone post transurethral resection of the prostate (turp). a rare case scenario

Conditions: Prostate Hyperplasia

Summary: prostatic resection cavity stone post transurethral resection of the prostate (turp). a rare case scenario

transurethral resection of the prostate (turp) is the gold standard surgical therapy for lower urinary tract symptoms (luts) owing to senile prostatic enlargement. following turp, luts may persist in a percentage of patients. persistent luts necessitates proper evaluation and management (1). in a rare case report, delayed occurrence of storage and obstructive voiding symptoms after turp can be caused by dystrophic calcification of the prostatic resection cavity and might be misinterpreted as post-turp infection. the mechanism of dystrophic calcification entails minimizing tissue trauma by cautious removal of calcifications rather than performing extensive re-turp (2). in our case, a rare presentation of storage luts as result of prostatic cavity stone extending into the bladder with same continuum, elicite the core issue of post turp storage luts.

Eligibility criteria:
inclusion criteria: * patient with prostatic fossa stone post turp exclusion criteria: * none
prospective comparative study about treatment of asymptomatic bacteriuria in kidney transplant recipients.

Conditions: Asymptomatic Bacteriuria

Summary: antimicrobial treatment of asymptomatic bacteriuria (ab) in kidney transplant recipients (ktr) is controversial. the investigators performed a comparative, parallel-group, randomized, open-label study to assess, in a real clinical setting, the feasibility of and benefit derived from systematic search and antimicrobial treatment of all episodes of ab.

all patients undergoing kt between january 2011 and december 2013 in a tertiary-care center with an active transplantation program were systematically searched for ab within the first 2 years after transplantation on a regular basis. during the first 2 months after transplantation all episodes of ab were treated. thereafter, patients were assigned, according to a computer-generated randomization sequence, to group a (systematic antimicrobial treatment of all episodes of ab) or group b (no treatment). treatment was chosen according to the results of the urine culture.

Eligibility criteria:
inclusion criteria: * adult patients developing asymptomatic bacteriuria beyond 2 months after transplantation. exclusion criteria: * \<18 years old * pregnant women * kidney-pancreas transplantation * double j stent catheterization at the momento of randomization * permanent vesical catheter

Keywords: asymptomatic bacteriuria kidney transplant recipients pyelonephritis
the teen marijuana check-up

Conditions: Cannabis Abuse; Cannabis Dependence

Summary: this behavioral research is an efficacy trial evaluating an intervention called "the teen marijuana check-up" with non-treatment seeking adolescent marijuana users.

three hundred adolescents who smoke marijuana (ages 14-19), recruited in four seattle-area high schools, will be enrolled in the trial. participants will be recruited either through in-class presentations focusing on marijuana or via referrals from school staff. they will first be assessed regarding use of marijuana, alcohol, and other drugs, as well as pertinent attitudes and goals. participants will then be randomly assigned to one of three conditions. * the experimental intervention is a two-session motivational enhancement treatment. a personalized feedback report, containing information from the participant's assessment as well as normative comparison data, is reviewed, with the health educator employing motivational interviewing strategies intended to enhance motivation for reduction or cessation of marijuana use. specific goals for change and behavior change strategies are discussed with participants who wish support to change their marijuana use. * the comparison condition involves two educational sessions focusing on the health and behavioral effects of marijuana. * the third condition (delayed treatment control) involves a minimal baseline assessment followed three months later by a reassessment interview. those assigned to this condition will then be given their choice of either active treatment. following completion of their two intervention sessions, participants in the two active treatments will be offered an additional four sessions of cognitive-behavioral skills training in which the focus is strategies in quitting marijuana. all participants will be reassessed at 3 and 12 months following their initial assessment interviews.

Eligibility criteria:
inclusion criteria: individuals who contact the project will be screened according to the following inclusion criteria: * age (14-19 years old), * grade level (freshmen through seniors) and * marijuana use (smoked 9 or more days in past 30). exclusion criteria: individuals will be excluded if: * they are not fluent in english, * they have a thought disorder that precludes full participation, * they refuse to accept randomization to condition. in addition to the inclusion and exclusion criteria, participants who appear to be in psychological or physical distress will be assessed further and referred to other services as appropriate. the need for other services will not necessarily preempt participation in the tmcu unless the individual is incapable or unwilling to complete the protocol. as was the case in our stage 1b trial, all ineligible applicants will be offered a single feedback session, and the strategies that work booklet will be offered to those who indicate any interest in reducing or quitting marijuana use.

Keywords: cannabis marijuana
evaluate clinical and radiological outcomes after limb reconstruction using monorail fixator over intramedullary nailing in tibial open fractures with bone loss

Conditions: Open Fracture Tibia

Summary: road traffic accidents (rta) is the most common cause of open fractures of long bones, increase in rta leading to increase of complex non-unions incidence. the participants are usually undergoing multiple surgeries for healing or to eradicate infection, which in turn leading to loss of bone and soft tissues and require skin grafting, muscle pedicle graft or bone grafting. sometimes the participants end up with deformity, limb length discrepancy, joints stiffness, disuse osteoporosis and muscle atrophy after management


Eligibility criteria:
inclusion criteria: * age from 18-60 years old. * open grade ii, open grade iii (a \& b) diaphyseal fractures of tibia (judged after primary and/or secondary to debridement). * bone defect \< 10 cm. * patients with injury severity score (iss) \< 17. exclusion criteria: * massive bone defect \> 10 cm. * patients with iss \> 17, polytrauma patient. * age \ 60 years old. * associated vascular injury ischemic limb.
ve202 in patients with mild-to-moderate ulcerative colitis

Conditions: Ulcerative Colitis; Colitis, Ulcerative

Summary: a phase 2 study to evaluate the safety, efficacy, and microbiota changes of ve202 in patients with mild to moderate ulcerative colitis (uc).

a phase 2 double-blind, placebo-controlled, randomized study to evaluate the safety, efficacy, and microbiota changes of ve202 in biologic-naïve patients with mild to moderate uc. in parts 1 and 2 of the study, patients will receive ve202 or placebo for 8 weeks or 2 weeks. in part 3, patients will be followed for safety for 1 year from the start of treatment.

Eligibility criteria:
key inclusion criteria 1. 18 to 75 years of age 2. documented clinical and endoscopic diagnosis of uc at least 3 months prior to randomization 3. active mild to moderate uc, as defined by the following: 1. disease that extends at least 15 cm from the anal verge 2. a modified mayo score of 4 to 8 with: (i.) mayo endoscopic subscore of ≥ 2 based on screening flexible sigmoidoscopy; (ii.) rectal bleeding score of ≥ 1 4. has never received a biologic agent, janus kinase inhibitor, or sphingosine-1-phosphate modulator for the treatment of uc 5. if receiving corticosteroids, dose must be stable for at least 4 weeks before randomization 6. doses of other allowable uc medications must be stable for at least 8 weeks before randomization key exclusion criteria 1. known history of crohn's disease (cd) or indeterminate colitis 2. a known diagnosis of primary sclerosing cholangitis 3. allergy to ve202 or any of its components 4. allergy to vancomycin or any of its components 5. a diagnosis of any non-ibd diarrheal illness (eg, clostridioides difficile, celiac disease, parasitic infection) within 3 months prior to randomization 6. use of probiotics or herbal, botanical, or traditional medicinal preparations within the 2 weeks prior to randomization (consumption of food products such as yogurt, kefir, kombucha, and herbal teas is permissible) 7. receipt of fecal microbiota transplantation (fmt) or other fecal-derived preparation within 6 months prior to randomization 8. prior colectomy, ostomy, or other intestinal surgery (excluding cholecystectomy or appendectomy) 9. receipt of any investigational biologic within 60 days or 5 half-lives prior to randomization, whichever is longer

Keywords: ulcerative colitis ve202 vedanta clostridia
prognostic markers for a better follow-up in head and neck cancer.

Conditions: Head and Neck Cancer

Summary: to identify tumor specific dna mutations and aberrations and to follow these in blood over time to predict treatment response/survival and secondly to correlate presence of these markers in blood to pathological parameters (lvi, pn, wpoi and margins), radiological findings and to tumor stage.


Eligibility criteria:
inclusion criteria: * patient diagnosed with head and neck cancer * treatment includes surgery * consent to participate exclusion criteria: * no consent * age below 18 years * no surgery * no tumor material to sample